⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OGN News
Organon & Co.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
globenewswire.com
XOMA
OGN
RMAX
SLNO
Halper Sadeh LLC is Investigating Whether AVNS, OGN, ESQ, VRE are Obtaining Fair Deals for their Shareholders
globenewswire.com
AVNS
OGN
ESQ
VRE
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?
prnewswire.com
OGN
TBRG
CYCN
La Comisión Europea (CE) aprueba POHERDY ® (pertuzumab) de Henlius y Organon, el primer biosimilar de PERJETA (pertuzumab) autorizado en Europa
businesswire.com
OGN
Europäische Kommission erteilt Marktzulassung für POHERDY ® (Pertuzumab) von Henlius und Organon, das erste in Europa zugelassene Biosimilar zu PERJETA (Pertuzumab)
businesswire.com
OGN
La Commissione Europea (CE) approva POHERDY ® (pertuzumab), messo a punto da Henlius e Organon, il primo biosimilare di PERJETA (pertuzumab) approvato in Europa
businesswire.com
OGN
La Commission européenne (CE) approuve le POHERDY ® (pertuzumab) de Henlius et Organon, premier médicament biosimilaire du PERJETA (pertuzumab) autorisé en Europe
businesswire.com
OGN
Europese Commissie (EC) keurt POHERDY ® (pertuzumab) van Henlius en Organon goed, de eerst goedgekeurde biosimilar voor PERJETA (pertuzumab) in Europa
businesswire.com
OGN
Europese Commissie (EC) keurt POHERDY ® (pertuzumab) van Henlius en Organon goed, de eerst goedgekeurde biosimilar voor PERJETA (pertuzumab) in Europa
businesswire.com
OGN
Form 8-K
sec.gov
OGN